NBRV Key Statistics, Chart & Performance
The current stock price of NBRV is 1.42 USD. In the past month the price decreased by -5.96%. In the past year, price decreased by -69.25%.
NBRV Latest News, Press Relases and Analysis
NBRV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.19 | 939.37B | ||
| JNJ | JOHNSON & JOHNSON | 19.9 | 497.62B | ||
| MRK | MERCK & CO. INC. | 11.08 | 242.29B | ||
| PFE | PFIZER INC | 8.06 | 146.58B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.81 | 104.25B | ||
| ZTS | ZOETIS INC | 18.62 | 52.03B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.31 | 22.09B | ||
| VTRS | VIATRIS INC | 4.98 | 13.36B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.19 | 10.58B | ||
| CORT | CORCEPT THERAPEUTICS INC | 96.94 | 8.97B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.52B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.13B |
Related stock screener links
About NBRV
Company Profile
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the commercialization and development of novel anti-infective agents to treat infections. The firm is engaged in the commercialization, research and development of novel anti-infective agents to treat serious infections. Its products include SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO. SIVEXTRO product is an oxazolidinone class antibiotic to treat susceptible Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). XENLETA product is designed to inhibit the synthesis of a specific protein on the bacterial ribosome, which is required for bacteria to grow, by binding with high affinity and specificity at molecular targets that are different than other available antibiotic classes causing cell death. CONTEPO is an investigational IV antibiotic in the United States with a spectrum of Gram-negative and Gram-positive activity, including activity against MDR strains, such as extended-spectrum β-lactamase-, or ESBL-producing Enterobacteriaceae.
Company Info
NABRIVA THERAPEUTICS PLC
Alexandra House Office 225/227,, The Sweepstakes,, Ballsbridge
DUBLIN 19406 IE
CEO: Theodore Schroeder
Employees: 39
Phone: 3536108166640.0
NABRIVA THERAPEUTICS PLC / NBRV FAQ
What does NBRV do?
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the commercialization and development of novel anti-infective agents to treat infections. The firm is engaged in the commercialization, research and development of novel anti-infective agents to treat serious infections. Its products include SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO. SIVEXTRO product is an oxazolidinone class antibiotic to treat susceptible Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). XENLETA product is designed to inhibit the synthesis of a specific protein on the bacterial ribosome, which is required for bacteria to grow, by binding with high affinity and specificity at molecular targets that are different than other available antibiotic classes causing cell death. CONTEPO is an investigational IV antibiotic in the United States with a spectrum of Gram-negative and Gram-positive activity, including activity against MDR strains, such as extended-spectrum β-lactamase-, or ESBL-producing Enterobacteriaceae.
What is the current price of NBRV stock?
The current stock price of NBRV is 1.42 USD.
Does NABRIVA THERAPEUTICS PLC pay dividends?
NBRV does not pay a dividend.
How is the ChartMill rating for NABRIVA THERAPEUTICS PLC?
NBRV has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is NABRIVA THERAPEUTICS PLC worth?
NABRIVA THERAPEUTICS PLC (NBRV) has a market capitalization of 4.55M USD. This makes NBRV a Nano Cap stock.
Who owns NABRIVA THERAPEUTICS PLC?
You can find the ownership structure of NABRIVA THERAPEUTICS PLC (NBRV) on the Ownership tab.
NBRV Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NBRV. When comparing the yearly performance of all stocks, NBRV is a bad performer in the overall market: 92.64% of all stocks are doing better.
NBRV Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NBRV. NBRV has a bad profitability rating. Also its financial health evaluation is rather negative.
NBRV Financial Highlights
Over the last trailing twelve months NBRV reported a non-GAAP Earnings per Share(EPS) of -18.63. The EPS increased by 20.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NBRV Forecast & Estimates
6 analysts have analysed NBRV and the average price target is 1.02 USD. This implies a price decrease of -28.17% is expected in the next year compared to the current price of 1.42.
For the next year, analysts expect an EPS growth of 49.57% and a revenue growth 89.23% for NBRV